An interventional study of TI stimulation device (nerviox-1000) in Obsessive-Compulsive Disorder (OCD), sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center — 16 open to participants now, 16 under way, none of them phase 3. Obsessive-Compulsive Disorder · Shanghai Mental Health Center.
Among the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, this one is the 23rd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 22 with no phase, reaches primary completion later than 7 of the 15 other live ones, and was the 23rd registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →16 of the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–55 · Healthy volunteers
Shanghai Mental Health Center · Sites in China
Ages 18–65
Shanghai Mental Health Center · Sites in China
Ages 7–17 · Healthy volunteers
Shanghai Mental Health Center · Sites in China
Ages 18–60
Shanghai Mental Health Center · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 1
First in 2014; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 60 across the 25 interventional studies, 125 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 95 are open to participants now.
7 of the studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT07115615Shanghai Mental Health CenterExploring the Efficacy of Accelerated Transcranial Direct Current Stimulation (tDCS) as Adjunct to Pharmacotherapy in the Treatment of Obsessive-compulsive Disorder | 2026-12-31 |
| NCT07031544Shanghai Mental Health CenterEfficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder | 2027-03-31 |
| NCT07113652Shanghai Mental Health CenterThe Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder | 2027-06 |
| NCT04539951Shanghai Mental Health CenterPragmatic Trial of Obsessive-compulsive Disorder | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy of Temporal Interference (TI) stimulation in treating patients with obsessive-compulsive disorder (OCD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) and electroencephalography (EEG).
This randomized, blind, multi-phase clinical trial aims to evaluate the efficacy of Temporal Interference (TI) stimulation in patients with treatment obsessive-compulsive disorder (OCD), and to compare the effects of stimulating different brain regions.
The study includes three phases:
Stimulation is delivered twice daily for 7 days in each phase, followed by follow-up assessments for up to 4 weeks. Comprehensive clinical assessments, self-reported symptom scales, magnetic resonance imaging (MRI), electroencephalography (EEG), and cognitive function tests are conducted before and after each phase to ensure data consistency. Additionally, clinical assessments and self-reported scales are repeated 1 week after the end of each treatment phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to NAcc-BNST group will receive stimulation targeting the NAcc in Phase 1 and the BNST in Phase 2. During the exploratory phase, based on participants' preferences, they will be randomly allocated to receive stimulation targeting one of the following regions: the caudate nucleus, the putamen, or the amygdala.
Device: TI stimulation device (nerviox-1000)
Participants assigned to BNST-NAcc group will receive stimulation targeting the BNST in Phase 1 and the NAcc in Phase 2. During the exploratory phase, based on participants' preferences, they will be randomly allocated to receive stimulation targeting one of the following regions: the caudate nucleus, the putamen, or the amygdala.
Device: TI stimulation device (nerviox-1000)
Participants assigned to the Sham-NAcc or Sham-BNST groups will receive sham stimulation in Phase 1, followed by active stimulation targeting the NAcc or the BNST in Phase 2. During the exploratory phase, based on participants' preferences, they will be randomly allocated to receive stimulation targeting one of the following regions: the caudate nucleus, the putamen, or the amygdala.
Device: TI stimulation device (nerviox-1000)
The TI stimulation device (nerviox-1000) delivers temporally interfering electrical fields with a 130 Hz envelope frequency, generated by high-frequency carrier waves. The stimulation is applied for 20 minutes per session, with a peak current of 3-4 mA per channel, adjusted based on individual tolerance. The stimulation targets include the nucleus accumbens, bed nucleus of the stria terminalis, amygdala, caudate nucleus, and putamen. Stimulation is administered twice daily, with each treatment phase lasting 7 consecutive days. Sham stimulation uses identical electrode placement and setup as active stimulation. A brief 30-second ramp-up is applied to mimic real stimulation, followed by rapid reduction to 0 mA or minimal current. A 1 mA "tail" current is delivered in the final 30 seconds to simulate the tapering effect of active stimulation.
Obsessive-compulsive symptoms improvement
Obsessive-compulsive symptom severity will be assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a 10-item clinician-rated scale with a total score range of 0 to 40. Higher total scores indicate more severe obsessive-compulsive symptoms.
Time frame: phase-specific baseline and 1 week after the end of each phase of TI treatment
Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 22 months is below that.
Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →
Shanghai Mental Health Center →